Canaccord Genuity Maintains a 'Buy' on Medifast (MED); Limited Downside, But Waiting For Clarity To Upside

Canaccord Genuity maintains a 'Buy' on Medifast (NYSE: MED) price target raised from $16 to $19.

Analyst, Scott Van Winkle, said, "We maintain our rating as we look for visibility on health coach trends in the Take Shape for Life channel and as earnings pressure from the clinic expansion subsides...At 13x our forward earnings estimate (ex-cash) and 6x our EBITDA forecast, we believe the shares should have limited downside"

For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.

Shares of Medifast closed at $18.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer